Chronic Hepatitis B
Conditions
Keywords
Chronic Hepatitis B
Brief summary
The study objective is to evaluate the safety and effectiveness of different doses of Metacavir Enteric-coated Capsules in treatment of chronic hepatitis B,as well as to find an appropriate clinical dosage by comparing the effect of different doses of treatment,in order to provide references of clinical trial of the next phase.
Detailed description
180 eligible subjects will be included.According to the set grouping method of dose escalation.Subjects will be randomized in a 1:1:1:1 proportion of Metacavir Enteric-coated Capsules(80mg/160mg/320mg) group,positive control group or placebo control group.Each group has 36 subjects. 1.Subjects will use the study medication(2 hours before or after meal,once a day) from Visit 3 to Visit 5. 1. Metacavir Enteric-coated Capsules 80mg Group:Metacavir Enteric-coated Capsules 80mg,Metacavir Enteric-coated Capsules Placebo 240mg,Adefovir Dipivoxil Capsule Placebo 10mg; 2. Metacavir Enteric-coated Capsules 160mg Group:Metacavir Enteric-coated Capsules 160mg,Metacavir Enteric-coated Capsules Placebo 160mg,Adefovir Dipivoxil Capsule Placebo 10mg; 3. Metacavir Enteric-coated Capsules 320mg Group:Metacavir Enteric-coated Capsules 320mg,Adefovir Dipivoxil Capsule Placebo 10mg; 4. Positive Control(Adefovir Dipivoxil Capsule) Group:Metacavir Enteric-coated Capsules Placebo 320mg,Adefovir Dipivoxil Capsule 10mg; 5. Placebo Control Group:Metacavir Enteric-coated Capsules Placebo 320mg,Adefovir Dipivoxil Capsule Placebo 10mg;
Interventions
DRUGMetacavir Enteric-coated Capsules 80mg
Metacavir Enteric-coated Capsules 80mg
DRUGMetacavir Enteric-coated Capsules 160mg
Metacavir Enteric-coated Capsules 160mg
DRUGMetacavir Enteric-coated Capsules 320mg
Metacavir Enteric-coated Capsules 320mg
DRUGMetacavir Enteric-coated Capsules Placebo 240mg
Metacavir Enteric-coated Capsules Placebo 240mg
DRUGMetacavir Enteric-coated Capsules Placebo 160mg
Metacavir Enteric-coated Capsules Placebo 160mg
DRUGMetacavir Enteric-coated Capsules Placebo 320mg
Metacavir Enteric-coated Capsules Placebo 320mg
DRUGAdefovir Dipivoxil Capsule10mg
Adefovir Dipivoxil Capsule10mg
DRUGAdefovir Dipivoxil Capsule Placebo 10mg
Adefovir Dipivoxil Capsule Placebo 10mg
Sponsors
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Are at least 18 years of age and no older than 65; * Subjects,with an established clinical history of HBV at Screening,has a positive HBsAg test(\>6months) regardless of a positive/negative HBeAg test; * At Screening,HBV-DNA\>10\^5 copies/ml in HBeAg positive or HBV-DNA\>10\^4 copies/ml in HBeAg negative(HBV-DNA was evaluated by polymerase chain reaction fluorescent labeling.); * Subjects with abnormal liver function test defined as alanine aminotransferase(ALT) was 2\ 10 times upper limit of normal in HBeAg positive or 1.5\ 10 times upper limit of normal in HBeAg negative; * Subjects who are willing to require any other treatment for anti-hepatitis B during the study period; * Subjects who are willing to take measures for effective non-pharmaceutical contraception; * Given their signed written informed consent to participate;
Exclusion criteria
* Subjects with hepatitis C(HCV),hepatitis D(HDV),autoimmune hepatitis,hereditary liver disease or any other active hepatitis; * A positive human immunodeficiency virus(HIV) test result; * Subjects,who in the opinion of the investigator,have a current diagnosis of hepatocellular carcinoma or serum α-fetoprotein(AFP)\>100ug/L; * Subjects with severe hepatitis or decompensated liver disease defined as hepatic encephalopathy,ascites,low protein blood syndrome(albumin ≤30g/l) or variceal bleeding; * Serum Creatinine(SCr) exceeds upper limit of normal; * At Screening,ALT\>10 times upper limit of normal,Total Bilirubin(TBIL)\>double upper limit of normal or transient hepatic decompensation caused by condition aggravation; * Subjects who required treatment with nucleoside antiviral drugs such as lamivudine,Adefovir dipivoxil,Telbivudine,Tenofovir disoproxil or Entecavir before Screening; * Subjects who require treatment with interferon-α，thymosin α-1 or other antiviral therapy,immunosuppressive agents,immune modulators within 6 months before Screening; * Subjects with cardiac disease,hematological system disease,cancer,impaired immunity or psychiatric disease; * Hemoglobin\<10g/dl,white blood cell count\<3.5 10\^9/L,platelets\<80 10\^9/L; * Subjects,who in the opinion of the investigator,have a current diagnosis of pancreatitis pre-dose within 24 weeks; * History of hypersensitivity or allergy to any of the study drugs; * Subjects who participate in other clinical trials within 3 months prior to Screening; * Women who are pregnant or lactating or planning a pregnancy recently; * Subjects in the opinion of the investigator,could not participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment. | 12 weeks | The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment.（Unit：log10) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-chronic hepatitis B | 12 weeks | 1. The proportion of subjects whose HBV-DNA are down to double logarithms at Week 12 of treatment.(Unit：%) 2. The proportion of subjects whose HBV-DNA are not detected or less than upper limit of normal at Week 12 of treatment.(Unit：%) 3. The proportion of subjects (HBeAg positive at baseline) whose is changed at Week 12 of treatment.(Unit：%) 4. The proportion of subjects whose HBsAg is changed to negative at Week 12 of treatment.(Unit：%) |
| Incidence of Adverse Events(AEs) | 48 weeks | — |
Countries
China
Contacts
Primary ContactMaorong Wang
Outcome results
None listed